<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330184</url>
  </required_header>
  <id_info>
    <org_study_id>2013KTZB</org_study_id>
    <nct_id>NCT03330184</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level</brief_title>
  <official_title>Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yan'an University Affiliated Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Aerospace Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Gaoxin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang'An Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yan'an people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shangluo Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine&#xD;
      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with&#xD;
      prediabetes and to detect the potential mechanism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota may play an important role in patients with prediabetes. Berberine, which is&#xD;
      usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in&#xD;
      vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut&#xD;
      microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim&#xD;
      of this study is to assess the beneficial effects of Bifidobacterium and Berberine&#xD;
      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with&#xD;
      prediabetes and to detect the potential mechanism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of absolute value of fasting plasma glucose (mmol/L)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Fasting plasma glucose will be measured during oral glucose tolerance test (OGTT) by glucose oxidase method at baseline and week 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of absolute value of 2-hour postprandial plasma glucose (mmol/L)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>2-hour postprandial plasma glucose will be measured during OGTT by glucose oxidase method at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of HbA1c (%)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>HbA1c will be tested in plasma by high-performance liquid chromatography at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of systolic pressure (mmHg)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Systolic pressure will be measured by mercurial sphygmomanometer using the standard methods at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of diastolic pressure (mmHg)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Diastolic pressure will be measured by mercurial sphygmomanometer using the standard methods at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of serum total cholesterol (mmol/L)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Serum total cholesterol will be measured by fully automatic biochemical analyser at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of low-density lipoprotein cholesterol (mmol/L)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Serum low-density lipoprotein cholesterol will be measured by fully automatic biochemical analyser at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of high-density lipoprotein cholesterol (mmol/L)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Serum high-density lipoprotein cholesterol will be measured by fully automatic biochemical analyser at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of triglycerides (mmol/L)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Serum triglycerides will be measured by fully automatic biochemical analyser at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of absolute value of body weight (kg)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Body weight will be measured by weighing scale using the standard methods at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of absolute value of body mass index (BMI) (kg/m^2)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2 at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of homeostasis model assessment (HOMA) index</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Fasting serum insulin and fasting plasma glucose will be calculated for HOMA index at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of insulin early-phase secretion index</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Fasting serum insulin and 30 min post serum insulin during OGTT will be calculated for early-phase secretion index at baseline and week 16 .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of insulin late-phase secretion index</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Fasting serum insulin and 2-hour post serum insulin during OGTT will be calculated for late-phase secretion index at baseline and week 16 .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of level of GLP-1(pmol/L)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>GLP-1 will be measured in serum by ELISA KIT at baseline and week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of abundances of gut microbiota (%)</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>Fecal samples will be measured by metagenomic sequencing to obtain abundances of gut microbiota at baseline and week 16.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Berberine Hydrochloride</condition>
  <arm_group>
    <arm_group_label>Berberine Hydrochloride group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2/day, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2/day, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Berberine Hydrochloride and Bifidobacterium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2/day, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine Hydrochloride group</intervention_name>
    <arm_group_label>Berberine Hydrochloride group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacterium group</intervention_name>
    <arm_group_label>Bifidobacterium group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine Hydrochloride and Bifidobacterium group</intervention_name>
    <arm_group_label>Berberine Hydrochloride and Bifidobacterium group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities.&#xD;
&#xD;
          -  Male or female between 18 and 70 years of old.&#xD;
&#xD;
          -  19≤Body mass index(BMI)≤30kg/m^2.&#xD;
&#xD;
          -  No participate in any clinical trial at least 3 months.&#xD;
&#xD;
          -  Diagnosed impaired fasting glucose(IFG) and impaired glucose tolerance(IGT) or&#xD;
             Diabetes.&#xD;
&#xD;
          -  In visit 1, 5.60mmol/L≤Fasting plasma glucose(FPG)&lt;8.0mmol/L; in visit 2,&#xD;
             6.1≤FPG&lt;8.0mmol/L or 7.8≤2-hour postprandial plasma glucose(2h-PPG) &lt;17mmol/L.&#xD;
&#xD;
          -  Females in child-bearing period should be given birth control.&#xD;
&#xD;
          -  No severe disease about heart, lung and kidney.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Diabetes patients with previously treated or untreated FPG ≥ 8 mmol/L or 2-h PPG ≥ 17&#xD;
             mmol/L;&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant, breastfeeding or intend to become&#xD;
             pregnant or are not using adequate contraceptive methods.&#xD;
&#xD;
          -  Those who are allergic to study drugs&#xD;
&#xD;
          -  Unable to cooperate&#xD;
&#xD;
          -  Abnormal liver function, ALT and AST are more than 2 times of the normal upper limit&#xD;
&#xD;
          -  Renal injury, blood creatinine ≥133 µmol/L&#xD;
&#xD;
          -  Poor blood pressure control, systolic blood pressure SBP≥160mmHg and/or diastolic&#xD;
             blood pressure DBP≥95mmHg&#xD;
&#xD;
          -  Patients with chronic gastrointestinal diseases (pancreatitis, inflammatory bowel&#xD;
             disease) and history of intestinal surgery&#xD;
&#xD;
          -  Patients with severe heart disease, such as heart failure, unstable angina pectoris,&#xD;
             acute myocardial infarction&#xD;
&#xD;
          -  Chronic hypoxic diseases such as emphysema, pulmonary heart disease&#xD;
&#xD;
          -  Having obvious diseases of the blood system&#xD;
&#xD;
          -  Persons with tumor diseases&#xD;
&#xD;
          -  Endocrine diseases, such as hyperthyroidism and hypercortisolism&#xD;
&#xD;
          -  Mental illness, abuse of alcohol, drugs or other substances&#xD;
&#xD;
          -  Persons with long-term oral or intravenous corticosteroid hormones therapy&#xD;
&#xD;
          -  Having stress conditions such as surgery, severe trauma, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiuhe Ph.D. Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology,Xi jing Hospital,Fourth Military Medical University</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifidobacterium</keyword>
  <keyword>People With Abnormal Glucose Level</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

